{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["COVID-19", "Ivermectin", "SARS-CoV-2", "hypoxia-inducible factor-alpha", "importin", "inflammation", "lung", "pandemics"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35686662", "DateCompleted": {"Year": "2022", "Month": "09", "Day": "02"}, "DateRevised": {"Year": "2023", "Month": "02", "Day": "02"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "06", "Day": "10"}], "Language": ["eng"], "ELocationID": ["10.1177/15353702221099579"], "Journal": {"ISSN": "1535-3699", "JournalIssue": {"Volume": "247", "Issue": "15", "PubDate": {"Year": "2022", "Month": "Aug"}}, "Title": "Experimental biology and medicine (Maywood, N.J.)", "ISOAbbreviation": "Exp Biol Med (Maywood)"}, "ArticleTitle": "Potential therapeutic effects of Ivermectin in COVID-19.", "Pagination": {"StartPage": "1388", "EndPage": "1396", "MedlinePgn": "1388-1396"}, "Abstract": {"AbstractText": ["COVID-19 is a critical pandemic that affected communities around the world, and there is currently no specific drug treatment for it. The virus enters the human cells via spikes and induces cytokine production and finally arrests the cell cycle. Ivermectin shows therapeutic potential for treating COVID-19 infection based on <i>in vitro</i> studies. Docking studies have shown a strong affinity between Ivermectin and some virulence factors of COVID-19. Notably, clinical evidence has demonstrated that Ivermectin with usual doses is effective by both the prophylactic and therapeutic approaches in all phases of the disease. Ivermectin inhibits both the adhesion and replication of the virus. Local therapy of the lung with Ivermectin or combination therapy may get better results and decrease the dose of the drug."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Research Center For Molecular Medicine, Hamadan University of Medical Sciences, Hamadan 9174223425, Iran."}, {"Identifier": [], "Affiliation": "Medicinal Plants and Natural Products Research Center, Hamadan University of Medical Sciences, Hamadan 9174223425, Iran."}], "LastName": "Barati", "ForeName": "Nastaran", "Initials": "N"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Medicine, Hamadan University of Medical Sciences, Hamadan 9174723895, Iran."}], "LastName": "Motavallihaghi", "ForeName": "Seyedmousa", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pars Advanced and Minimally Invasive Medical Manners Research Center, Pars Hospital, Iran University of Medical Sciences, Tehran 1415944911, Iran."}], "LastName": "Nikfar", "ForeName": "Banafsheh", "Initials": "B"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pars Advanced and Minimally Invasive Medical Manners Research Center, Pars Hospital, Iran University of Medical Sciences, Tehran 1415944911, Iran."}], "LastName": "Chaichian", "ForeName": "Shahla", "Initials": "S"}, {"Identifier": ["0000-0002-4376-1083"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medical Biotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad 8167994434, Iran."}], "LastName": "Momtazi-Borojeni", "ForeName": "Amir Abbas", "Initials": "AA"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Exp Biol Med (Maywood)", "NlmUniqueID": "100973463", "ISSNLinking": "1535-3699"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antiviral Agents"}, {"RegistryNumber": "70288-86-7", "NameOfSubstance": "Ivermectin"}], "MeshHeadingList": [{"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Antiviral Agents"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Ivermectin"}, {"QualifierName": [], "DescriptorName": "Lung"}, {"QualifierName": [], "DescriptorName": "Pandemics"}, {"QualifierName": [], "DescriptorName": "SARS-CoV-2"}, {"QualifierName": [], "DescriptorName": "COVID-19 Drug Treatment"}], "CoiStatement": "<b>Declaration of Conflicting Interests:</b> The author(s) declared no potential conflicts of interest with respect to\nthe research, authorship, and/or publication of this article."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Taguchi YH, Turki T. A new advanced in silico drug discovery method for novel coronavirus (SARS-CoV-2) with tensor decomposition-based unsupervised feature extraction. PLoS ONE 2020;15:e0238907", "ArticleIdList": ["PMC7485840", "32915876"]}, {"Citation": "Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care 2020;57:279\u201383", "ArticleIdList": ["PMC7270792", "32173110"]}, {"Citation": "Naqvi AAT, Fatima K, Mohammad T, Fatima U, Singh IK, Singh A, Atif SM, Hariprasad G, Hasan GM, Hassan MI. Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: structural genomics approach. Biochim Biophys Acta Mol Basis Dis 2020;866:165878", "ArticleIdList": ["PMC7293463", "32544429"]}, {"Citation": "Momtazi-Borojeni AA, Banach M, Reiner \u017d, Pirro M, Bianconi V, Al-Rasadi K, Sahebkar A. Interaction between coronavirus S-protein and human ACE2: hints for exploring efficient therapeutic targets to treat COVID-19. Angiology 2021;72:122\u201330", "ArticleIdList": ["32864982"]}, {"Citation": "Sungnak W, Huang N, B\u00e9cavin C, Berg M, Queen R, Litvinukova M, Talavera-L\u00f3pez C, Maatz H, Reichart D, Sampaziotis F, Worlock KB, Yoshida M, Barnes JL, HCA Lung Biological Network. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med 2020;26:681\u20137", "ArticleIdList": ["PMC8637938", "32327758"]}, {"Citation": "Coutard B, Valle C, de Lamballerie X, Canard B, Seidah NG, Decroly E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res 2020;176:104742.", "ArticleIdList": ["PMC7114094", "32057769"]}, {"Citation": "Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003;426:450\u20134", "ArticleIdList": ["PMC7095016", "14647384"]}, {"Citation": "Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004;203:631\u20137", "ArticleIdList": ["PMC7167720", "15141377"]}, {"Citation": "Xia S, Lan Q, Su S, Wang X, Xu W, Liu Z, Zhu Y, Wang Q, Lu L, Jiang S. The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin. Signal Transduct Target Ther 2020;5:92.", "ArticleIdList": ["PMC7289711", "32532959"]}, {"Citation": "\nJohnson BA, Xie X, Kalveram B, Lokugamage KG, Muruato A, Zou J, Zhang X, Juelich T, Smith JK, Zhang L. Furin cleavage site is key to\nSARS-CoV-2 pathogenesis.\nbioRxiv\n2020, https://www.biorxiv.org/content/10.1101/2020.08.26.268854v1", "ArticleIdList": ["10.1101/2020.08.26.268854v1", "PMC8175039", "33494095"]}, {"Citation": "\nCai Y, Zhang J, Xiao T, Peng H, Sterling SM, Walsh RM, Rawson S, Rits-Volloch S, Chen B. Distinct conformational states of\nSARS-CoV-2 spike protein.\nbioRxiv\n2020, https://www.biorxiv.org/content/10.1101/2020.05.16.099317v1", "ArticleIdList": ["10.1101/2020.05.16.099317v1", "PMC7263552", "32511405"]}, {"Citation": "Anand P, Puranik A, Aravamudan M, Venkatakrishnan A, Soundararajan V. SARS-CoV-2 strategically mimics proteolytic activation of human ENaC. eLife 2020;9:e58603", "ArticleIdList": ["PMC7343387", "32452762"]}, {"Citation": "Bouhaddou M, Memon D, Meyer B, White KM, Rezelj VV, Marrero MC, Polacco BJ, Melnyk JE, Ulferts S, Kaake RM. The global phosphorylation landscape of SARS-CoV-2 infection. Cell 2020;182:685\u2013712.e19", "ArticleIdList": ["PMC7321036", "32645325"]}, {"Citation": "Romagnoli S, Peris A, De Gaudio AR, Geppetti P. SARS-CoV-2 and COVID-19: from the bench to the bedside. Physiol Rev 2020;100:1455.", "ArticleIdList": ["PMC7347954", "32496872"]}, {"Citation": "Crump A. Ivermectin: enigmatic multifaceted \u201cwonder\u201d drug continues to surprise and exceed expectations. J Antibiot 2017;70:495\u2013505", "ArticleIdList": ["28196978"]}, {"Citation": "\u014cmura S, Shiomi K. Discovery, chemistry, and chemical biology of microbial products. Pure Appl Chem 2007;79:581\u201391"}, {"Citation": "\nGuo C, Snowden F. Chairman Mao\u2019s malarial\nlegacy.\nThe Yale Historical Review, p. 56,\nhttps://historicalreview.yale.edu/sites/default/files/yhr18.pdf"}, {"Citation": "Juarez M, Schcolnik-Cabrera A, Due\u00f1as-Gonzalez A. The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug. Am J Cancer Res 2018;8:317\u201331", "ArticleIdList": ["PMC5835698", "29511601"]}, {"Citation": "Intuyod K, Hahnvajanawong C, Pinlaor P, Pinlaor S. Anti-parasitic drug ivermectin exhibits potent anticancer activity against gemcitabine-resistant cholangiocarcinoma in vitro. Anticancer Res 2019;39:4837\u201343", "ArticleIdList": ["31519586"]}, {"Citation": "Razazan A, Nicastro J, Slavcev R, Barati N, Arab A, Mosaffa F, Jaafari MR, Behravan J. Lambda bacteriophage nanoparticles displaying GP2, a HER2/neu derived peptide, induce prophylactic and therapeutic activities against TUBO tumor model in mice. Sci Rep 2019;9:2221.", "ArticleIdList": ["PMC6379380", "30778090"]}, {"Citation": "Barati N, Momtazi-Borojeni AA, Majeed M, Sahebkar A. Potential therapeutic effects of curcumin in gastric cancer. J Cell Physiol 2019;234: 2317\u201328", "ArticleIdList": ["30191991"]}, {"Citation": "Naghibi L, Yazdani M, Momtazi-Borojeni AA, Razazan A, Shariat S, Mansourian M, Arab A, Barati N, Arabsalmani M, Abbasi A, Saberi Z, Badiee A, Jalali SA, Jaafari MR. Preparation of nanoliposomes containing HER2/neu (P5+ 435) peptide and evaluation of their immune responses and anti-tumoral effects as a prophylactic vaccine against breast cancer. PLoS ONE 2020;15:e0243550", "ArticleIdList": ["PMC7728212", "33301467"]}, {"Citation": "Lloyd AE, Honey BL, John BM, Condren M. Treatment options and considerations for intestinal helminthic infections. J Pharm Technol 2014;30:130\u20139", "ArticleIdList": ["PMC5990147", "34860931"]}, {"Citation": "Campbell S, Soman-Faulkner K. Antiparasitic drugs. Treasure Island, FL: StatPearls Publishing, 2022"}, {"Citation": "Reza HAM, Rreza G, Nastaran B, Mousa M. Renal hydatid cyst; a rare infectious disease. Oxf Med Case Reports 2019;2019:omz011", "ArticleIdList": ["PMC6440275", "30949349"]}, {"Citation": "Motevalli Haghi SM, Najm M, Fakhar M, Gholami S, MotevalliHaghi S. Prevalence of Enterobius vermicularis infection among kindergartens of Sari and Babol cities during 2011. J Mazandaran Univ Med Sci 2013;22:240\u20132"}, {"Citation": "Heidary F, Gharebaghi R. Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. J Antibiot 2020;73:593\u2013602", "ArticleIdList": ["PMC7290143", "32533071"]}, {"Citation": "Chaccour C, Hammann F, Ram\u00f3n-Garc\u00eda S, Rabinovich NR. Ivermectin and COVID-19: keeping rigor in times of urgency. Am J Trop Med Hyg 2020;102:1156\u20137", "ArticleIdList": ["PMC7253113", "32314704"]}, {"Citation": "Guzzo CA, Furtek CI, Porras AG, Chen C, Tipping R, Clineschmidt CM, Sciberras DG, Hsieh JY, Lasseter KC. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol 2002;42:1122\u201333", "ArticleIdList": ["12362927"]}, {"Citation": "Bagheri E, Abnous K, Farzad SA, Taghdisi SM, Ramezani M, Alibolandi M. Targeted doxorubicin-loaded mesenchymal stem cells-derived exosomes as a versatile platform for fighting against colorectal cancer. Life Sci 2020;261:118369.", "ArticleIdList": ["32882265"]}, {"Citation": "Smit MR, Ochomo EO, Aljayyoussi G, Kwambai TK, Abong\u2019o BO, Chen T, Bousema T, Slater HC, Waterhouse D, Bayoh NM, Gimnig JE, Samuels AM, Desai MR, Phillips-Howard PA, Kariuki SK, Wang D, Ward SA, Ter Kuile FO. Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 2018;18:615\u201326", "ArticleIdList": ["29602751"]}, {"Citation": "Vora A, Arora VK, Behera D, Tripathy SK. White paper on Ivermectin as a potential therapy for COVID-19. Indian J Tuberc 2020;67:448\u201351", "ArticleIdList": ["PMC7434458", "32825892"]}, {"Citation": "Sharun K, Dhama K, Patel SK, Pathak M, Tiwari R, Singh BR, Sah R, Bonilla- Aldana DK, Rodriguez-Morales AJ, Leblebicioglu H. Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19. Ann Clin Microbiol Antimicrob 2020;19:23.", "ArticleIdList": ["PMC7261036", "32473642"]}, {"Citation": "\nGon\u00e7alves K, Vasconcelos A, Barbirato D, Vasconcelos C, Vasconcelos B. Therapeutic potential of ivermectin\nfor COVID-19.\nAuthorea Preprints\n2020, https://www.authorea.com/doi/full/10.22541/au.159050476.60928563", "ArticleIdList": ["10.22541/au.159050476.60928563"]}, {"Citation": "Banerjee K, Nandy M, Dalai CK, Ahmed SN. The battle against COVID 19 pandemic: what we need to know before we \u201ctest fire\u201d Ivermectin. Drug Res 2020;70:337\u201340", "ArticleIdList": ["PMC7417290", "32559771"]}, {"Citation": "Wagstaff KM, Sivakumaran H, Heaton SM, Harrich D, Jans DA. Ivermectin is a specific inhibitor of importin \u03b1/\u03b2-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochem J 2012;443:851\u20136", "ArticleIdList": ["PMC3327999", "22417684"]}, {"Citation": "Lundberg L, Pinkham C, Baer A, Amaya M, Narayanan A, Wagstaff KM, Jans DA, Kehn-Hall K. Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis Virus replication. Antiviral Res 2013;100:662\u201372", "ArticleIdList": ["24161512"]}, {"Citation": "G\u00f6tz V, Magar L, Dornfeld D, Giese S, Pohlmann A, H\u00f6per D, Kong B-W, Jans DA, Beer M, Haller O. Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import. Sci Rep 2016;6:23138.", "ArticleIdList": ["PMC4796820", "26988202"]}, {"Citation": "Mastrangelo E, Pezzullo M, De Burghgraeve T, Kaptein S, Pastorino B, Dallmeier K, de Lamballerie X, Neyts J, Hanson AM, Frick DN, Bolognesi M, Milani M. Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug. J Antimicrob Chemother 2012;67:1884\u201394", "ArticleIdList": ["PMC3888155", "22535622"]}, {"Citation": "Lv C, Liu W, Wang B, Dang R, Qiu L, Ren J, Yan C, Yang Z, Wang X. Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro and vivo. Antiviral Res 2018;159:55\u201362", "ArticleIdList": ["30266338"]}, {"Citation": "Yang SNY, Atkinson SC, Wang C, Lee A, Bogoyevitch MA, Borg NA, Jans DA. The broad spectrum antiviral ivermectin targets the host nuclear transport importin \u03b1/\u03b21 heterodimer. Antiviral Res 2020;177:104760.", "ArticleIdList": ["32135219"]}, {"Citation": "Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res 2020;178:104787.", "ArticleIdList": ["PMC7129059", "32251768"]}, {"Citation": "Pareek R, Saxena R, Saxena V. \u201cIvermectin\u201d\u2014a key in the bunch of keys to unlock the other activities including educational institutions in COVID-19 pandemic. Int J Sci Res 2020;9:939\u201350"}, {"Citation": "Yavuz S, \u00dcnal S. Antiviral treatment of COVID-19. Turk J Med Sci 2020;50:611\u20139", "ArticleIdList": ["PMC7195979", "32293834"]}, {"Citation": "DiNicolantonio JJ, Barroso J, McCarty M. Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19. Open Heart 2020;7:e001350", "ArticleIdList": ["PMC7476419", "32895293"]}, {"Citation": "Schmith VD, Zhou J, Lohmer LR. The approved dose of ivermectin alone is not the ideal dose for the treatment of COVID-19. Clin Pharmacol Ther 2020;108:762\u20135", "ArticleIdList": ["PMC7267287", "32378737"]}, {"Citation": "Formiga FR, Leblanc R, de Souza Rebou\u00e7as J, Farias LP, de Oliveira RN, Pena L. Ivermectin: an award-winning drug with expected antiviral activity against COVID-19. J Control Release 2021;329:758\u201361", "ArticleIdList": ["PMC7539925", "33038449"]}, {"Citation": "Bray M, Rayner C, No\u00ebl F, Jans D, Wagstaff K. Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors\u2019 responses. Antiviral Res 2020;178:104805.", "ArticleIdList": ["PMC7172803", "32330482"]}, {"Citation": "\nGorial FI, Mashhadani S, Sayaly HM, Dakhil BD, AlMashhadani MM, Aljabory AM, Abbas HM, Ghanim M, Rasheed JI. Effectiveness of ivermectin as add-on\ntherapy in COVID-19 management (pilot trial).\nmedRxiv\n2020, https://www.medrxiv.org/content/10.1101/2020.07.07.20145979v1", "ArticleIdList": ["10.1101/2020.07.07.20145979v1"]}, {"Citation": "\nRajter JC, Sherman M, Fatteh N, Vogel F, Sacks J, Rajter J-J. ICON (Ivermectin in COvid Nineteen)\nstudy: use of ivermectin is associated with lower mortality in\nhospitalized patients with COVID19.\nmedRxiv\n2020, https://www.medrxiv.org/content/10.1101/2020.06.06.20124461v2", "ArticleIdList": ["10.1101/2020.06.06.20124461v2", "PMC7550891", "33065103"]}, {"Citation": "\nPatel A, Desai S. Ivermectin in COVID-19 related\ncritical illness.\nSSRN J\n2020, https://www.isglobal.org/documents/10179/6022921/Patel+et+al.+2020+version+1.pdf"}, {"Citation": "Szente Fonseca SN, de Queiroz Sousa A, Wolkoff AG, Moreira MS, Pinto BC, Valente Takeda CF, Rebou\u00e7as E, Vasconcellos Abdon AP, Nascimento ALA, Risch HA. Risk of hospitalization for Covid-19 outpatients treated with various drug regimens in Brazil: comparative analysis. Travel Med Infect Dis 2020;38:101906.", "ArticleIdList": ["PMC7604153", "33137493"]}, {"Citation": "L\u00f3pez-Medina E, L\u00f3pez P, Hurtado IC, D\u00e1valos DM, Ramirez O, Mart\u00ednez E, D\u00edazgranados JA, O\u00f1ate JM, Chavarriaga H, Herrera S. Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial. JAMA 2021;325:1426\u201335", "ArticleIdList": ["PMC7934083", "33662102"]}, {"Citation": "DiNicolantonio JJ, Barroso-Aranda J, McCarty MF. Anti-inflammatory activity of ivermectin in late-stage COVID-19 may reflect activation of systemic glycine receptors. Open Heart 2021;8:e001655", "ArticleIdList": ["PMC8057070", "33875563"]}, {"Citation": "Audus KL, Knaub SR, Guillot FL, Schaeffer JM. The effect of protein binding on ivermectin uptake by bovine brain microvessel endothelial cells. Vet Res Commun 1992;16:365\u201377", "ArticleIdList": ["1494861"]}, {"Citation": "Lifschitz A, Virkel G, Sallovitz J, Sutra J, Galtier P, Alvinerie M, Lanusse C. Comparative distribution of ivermectin and doramectin to parasite location tissues in cattle. Vet Parasitol 2000;87:327\u201338", "ArticleIdList": ["10669102"]}, {"Citation": "Choudhury A, Das NC, Patra R, Bhattacharya M, Ghosh P, Patra BC, Mukherjee S. Exploring the binding efficacy of ivermectin against the key proteins of SARS-CoV-2 pathogenesis: an in silico approach. Future Virol 2021;16:277\u201391"}, {"Citation": "Bello M. Elucidation of the inhibitory activity of Ivermectin with host nuclear importin \u03b1 and several SARS-CoV-2 targets. J Biomol Struct Dyn. Epub ahead of print 10 April 2021. DOI: 10.1080/07391102.2021.1911857", "ArticleIdList": ["10.1080/07391102.2021.1911857", "PMC8054936", "33843474"]}, {"Citation": "Saha JK, Raihan M. The binding mechanism of ivermectin and levosalbutamol with spike protein of SARS-CoV-2. Struct Chem 2021;32:1985\u201392", "ArticleIdList": ["PMC8039806", "33867777"]}, {"Citation": "Lehrer S, Rheinstein PH. Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain attached to ACE2. In Vivo 2020;34:3023\u20136", "ArticleIdList": ["PMC7652439", "32871846"]}, {"Citation": "Kalhor H, Sadeghi S, Abolhasani H, Kalhor R, Rahimi H. Repurposing of the approved small molecule drugs in order to inhibit SARS-CoV-2 S protein and human ACE2 interaction through virtual screening approaches. J Biomol Struct Dyn 2022;40:1299\u2013315", "ArticleIdList": ["PMC7576931", "32969333"]}, {"Citation": "Low ZY, Yip AJW, Lal SK. Repositioning Ivermectin for Covid-19 treatment: molecular mechanisms of action against SARS-CoV-2 replication. Biochim Biophys Acta Mol Basis Dis 2022;1868:166294.", "ArticleIdList": ["PMC8526435", "34687900"]}, {"Citation": "Romano M, Ruggiero A, Squeglia F, Maga G, Berisio R. A structural view of SARS-CoV-2 RNA replication machinery: RNA synthesis, proofreading and final capping. Cells 2020;9:1267", "ArticleIdList": ["PMC7291026", "32443810"]}, {"Citation": "Gao Y, Yan L, Huang Y, Liu F, Zhao Y, Cao L, Wang T, Sun Q, Ming Z, Zhang L. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science 2020;368:779\u201382", "ArticleIdList": ["PMC7164392", "32277040"]}, {"Citation": "Sen Gupta PS, Biswal S, Panda SK, Ray AK, Rana MK. Binding mechanism and structural insights into the identified protein target of COVID-19 and importin-\u03b1 with in-vitro effective drug ivermectin. J Biomol Struct Dyn 2020;40:2217\u201326", "ArticleIdList": ["PMC7605516", "33111618"]}, {"Citation": "Mody V, Ho J, Wills S, Mawri A, Lawson L, Ebert MC, Fortin GM, Rayalam S, Taval S. Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents. Commun Biol 2021;4:93.", "ArticleIdList": ["PMC7817688", "33473151"]}, {"Citation": "Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 2003;300:1763\u20137", "ArticleIdList": ["12746549"]}, {"Citation": "Nukoolkarn V, Lee VS, Malaisree M, Aruksakulwong O, Hannongbua S. Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CLpro inhibitors. J Theor Biol 2008;254:861\u20137", "ArticleIdList": ["PMC7094092", "18706430"]}, {"Citation": "Jamalipour Soufi G, Iravani S. Potential inhibitors of SARS-CoV-2: recent advances. J Drug Target 2021;29:349\u201364", "ArticleIdList": ["33210953"]}, {"Citation": "Silvestrini L, Belhaj N, Comez L, Gerelli Y, Lauria A, Libera V, Mariani P, Marzullo P, Ortore MG, Palumbo Piccionello A. The dimer-monomer equilibrium of SARS-CoV-2 main protease is affected by small molecule inhibitors. Sci Rep 2021;11:9283.", "ArticleIdList": ["PMC8085067", "33927258"]}, {"Citation": "Littler DR, Gully BS, Colson RN, Rossjohn J. Crystal structure of the SARS-CoV-2 non-structural protein 9, Nsp9. iScience 2020;23:101258.", "ArticleIdList": ["PMC7282741", "32592996"]}, {"Citation": "Zaidi AK, Dehgani-Mobaraki P. The mechanisms of action of ivermectin against SARS-CoV-2\u2014an extensive review. J Antibiot 2022;75:60\u201371", "ArticleIdList": ["PMC8688140", "34931048"]}, {"Citation": "Park A, Iwasaki A. Type I and type III interferons\u2013induction, signaling, evasion, and application to combat COVID-19. Cell Host Microbe 2020;27:870\u20138", "ArticleIdList": ["PMC7255347", "32464097"]}, {"Citation": "Wang C, Sun M, Yuan X, Ji L, Jin Y, Cardona CJ, Xing Z. Enterovirus 71 suppresses interferon responses by blocking Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling through inducing karyopherin-\u03b11 degradation. J Biol Chem 2017;292:10262\u201374", "ArticleIdList": ["PMC5473229", "28455446"]}, {"Citation": "Seth C, Mas C, Conod A, Mueller J, Siems K, Kuciak M, Borges I, Ruiz i, Altaba A. Long-lasting WNT-TCF response blocking and epigenetic modifying activities of Withanolide F in human cancer cells. PLoS ONE 2016;11:e0168170", "ArticleIdList": ["PMC5156407", "27973612"]}, {"Citation": "Gupta KK, Xu Z, Castellino FJ, Ploplis VA. Plasminogen activator inhibitor-1 stimulates macrophage activation through Toll-like Receptor-4. Biochem Biophys Res Commun 2016;477:503\u20138", "ArticleIdList": ["27317488"]}, {"Citation": "Matsuyama T, Kubli SP, Yoshinaga SK, Pfeffer K, Mak TW. An aberrant STAT pathway is central to COVID-19. Cell Death Differ 2020;27:3209\u201325", "ArticleIdList": ["PMC7545020", "33037393"]}, {"Citation": "Yang D, Chu H, Hou Y, Chai Y, Shuai H, Lee AC-Y, Zhang X, Wang Y, Hu B, Huang X. Attenuated interferon and proinflammatory response in SARS-CoV-2\u2013infected human dendritic cells is associated with viral antagonism of STAT1 phosphorylation. J Infect Dis 2020;222:734\u201345", "ArticleIdList": ["PMC7337793", "32563187"]}, {"Citation": "Konno Y, Kimura I, Uriu K, Fukushi M, Irie T, Koyanagi Y, Sauter D, Gifford RJ, Nakagawa S, Sato K. SARS-CoV-2 ORF3b is a potent interferon antagonist whose activity is increased by a naturally occurring elongation variant. Cell Rep 2020;32:108185.", "ArticleIdList": ["PMC7473339", "32941788"]}, {"Citation": "Aluwihare P, Munger JS. What the lung has taught us about latent TGF-\u03b2 activation. Am J Respir Cell Mol Biol 2008;39:499\u2013502", "ArticleIdList": ["PMC2720085", "18927350"]}, {"Citation": "Han S, Mallampalli RK. The acute respiratory distress syndrome: from mechanism to translation. J Immunol 2015;194:855\u201360", "ArticleIdList": ["PMC4299926", "25596299"]}, {"Citation": "Dou Q, Chen H-N, Wang K, Yuan K, Lei Y, Li K, Lan J, Chen Y, Huang Z, Xie N. Ivermectin induces cytostatic autophagy by blocking the PAK1/Akt axis in breast cancer. Cancer Res 2016;76:4457\u201369", "ArticleIdList": ["27302166"]}, {"Citation": "de Melo GD, Lazarini F, Larrous F, Feige L, Kornobis E, Levallois S, Marchio A, Kergoat L, Hardy D, Cokelaer T. Attenuation of clinical and immunological outcomes during SARS-CoV-2 infection by ivermectin. EMBO Mol Med 2021;13:e14122", "ArticleIdList": ["PMC8350903", "34170074"]}, {"Citation": "Zhang X, Song Y, Ci X, An N, Ju Y, Li H, Wang X, Han C, Cui J, Deng X. Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice. Inflamm Res 2008;57:524\u20139", "ArticleIdList": ["19109745"]}, {"Citation": "Zhang X, Song Y, Xiong H, Ci X, Li H, Yu L, Zhang L, Deng X. Inhibitory effects of ivermectin on nitric oxide and prostaglandin E2 production in LPS-stimulated RAW 264.7 macrophages. Int Immunopharmacol 2009;9:354\u20139", "ArticleIdList": ["19168156"]}, {"Citation": "Viktorov AV. Ivermectin inhibits activation of Kupffer cells induced by lipopolysaccharide toxin. Antibiot Khimioter 2003;48:3\u20136", "ArticleIdList": ["13677129"]}, {"Citation": "Ci X, Li H, Yu Q, Zhang X, Yu L, Chen N, Song Y, Deng X. Avermectin exerts anti-inflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway. Fundam Clin Pharmacol 2009;23:449\u201355", "ArticleIdList": ["19453757"]}, {"Citation": "Wheeler M, Stachlewitz RF, Yamashina S, Ikejima K, Morrow AL, Thurman RG. Glycine-gated chloride channels in neutrophils attenuate calcium influx and superoxide production. FASEB J 2000;14:476\u201384", "ArticleIdList": ["10698962"]}, {"Citation": "McCarty MF, Iloki-Assanga S, Lujan LML, DiNicolantonio JJ. Activated glycine receptors may decrease endosomal NADPH oxidase activity by opposing ClC-3-mediated efflux of chloride from endosomes. Med Hypotheses 2019;123:125\u20139", "ArticleIdList": ["30696582"]}, {"Citation": "Shan Q, Haddrill JL, Lynch JW. Ivermectin, an unconventional agonist of the glycine receptor chloride channel. J Biol Chem 2001;276:12556\u201364", "ArticleIdList": ["11278873"]}, {"Citation": "Lynagh T, Webb TI, Dixon CL, Cromer BA, Lynch JW. Molecular determinants of ivermectin sensitivity at the glycine receptor chloride channel. J Biol Chem 2011;286:43913\u201324", "ArticleIdList": ["PMC3243547", "22033924"]}, {"Citation": "Wang Q, Lynch JW. A comparison of glycine-and ivermectin-mediated conformational changes in the glycine receptor ligand-binding domain. Int J Biochem Cell Biol 2012;44:335\u201340", "ArticleIdList": ["22094187"]}, {"Citation": "Wheeler M, Ikejema K, Enomoto N, Stacklewitz R, Seabra V, Zhong Z, Yin M, Schemmer P, Rose M, Rusyn I. Glycine: a new anti-inflammatory immunonutrient. Cel Mol Life Sci 1999;56:843\u201356", "ArticleIdList": ["11212343"]}, {"Citation": "Caly L, Wagstaff KM, Jans DA. Nuclear trafficking of proteins from RNA viruses: potential target for antivirals? Antiviral Res 2012;95:202\u20136", "ArticleIdList": ["22750233"]}, {"Citation": "Yang SN, Atkinson SC, Fraser JE, Wang C, Maher B, Roman N, Forwood JK, Wagstaff KM, Borg NA, Jans DA. Novel flavivirus antiviral that targets the host nuclear transport importin \u03b1/\u03b21 heterodimer. Cells 2019;8:281", "ArticleIdList": ["PMC6468590", "30909636"]}, {"Citation": "Azam F, Taban IM, Eid EE, Iqbal M, Alam O, Khan S, Mahmood D, Anwar MJ, Khalilullah H, Khan M. An in-silico analysis of ivermectin interaction with potential SARS-CoV-2 targets and host nuclear importin \u03b1. J Biomol Struct Dyn 2022;40:2851\u201364", "ArticleIdList": ["PMC7643422", "33131430"]}, {"Citation": "Azam F, Alabdullah NH, Ehmedat HM, Abulifa AR, Taban I, Upadhyayula S. NSAIDs as potential treatment option for preventing amyloid \u03b2 toxicity in Alzheimer\u2019s disease: an investigation by docking, molecular dynamics, and DFT studies. J Biomol Struct Dyn 2018;36:2099\u2013117", "ArticleIdList": ["28571516"]}, {"Citation": "Smith TG, Robbins PA, Ratcliffe PJ. The human side of hypoxia-inducible factor. Br J Haematol 2008;141:325\u201334", "ArticleIdList": ["PMC2408651", "18410568"]}, {"Citation": "Wilkins SE, Abboud MI, Hancock RL, Schofield CJ. Targeting protein\u2013protein interactions in the HIF system. ChemMedChem 2016;11:773\u201386", "ArticleIdList": ["PMC4848768", "26997519"]}, {"Citation": "Gilman NV. Analyses of the 2019 Nobel Prize in physiology or medicine: molecular machinery for cellular oxygen level response. Sci Technol Libr 2020;39:1\u201327"}, {"Citation": "Serebrovska ZO, Chong EY, Serebrovska TV, Tumanovska LV, Xi L. Hypoxia, HIF-1\u03b1, and COVID-19: from pathogenic factors to potential therapeutic targets. Acta Pharmacol Sin 2020;41:1539\u201346", "ArticleIdList": ["PMC7588589", "33110240"]}, {"Citation": "Morris DR, Qu Y, Agrawal A, Garofalo RP, Casola A. HIF-1\u03b1 modulates core metabolism and virus replication in primary airway epithelial cells infected with respiratory syncytial virus. Viruses 2020;12:1088", "ArticleIdList": ["PMC7601280", "32993138"]}, {"Citation": "Golan M, Mabjeesh NJ. SEPT9_i1 is required for the association between HIF-1\u03b1 and importin-\u03b1 to promote efficient nuclear translocation. Cell Cycle 2013;12:2297\u2013308", "ArticleIdList": ["PMC3755080", "24067372"]}, {"Citation": "Russo P, Bonassi S, Giacconi R, Malavolta M, Tomino C, Maggi F. COVID-19 and smoking: is nicotine the hidden link? Eur Respir J 2020;55:2001116.", "ArticleIdList": ["PMC7236819", "32341101"]}, {"Citation": "Leung JM, Yang CX, Sin DD. COVID-19 and nicotine as a mediator of ACE-2. Eur Respir J 2020;55:2001261.", "ArticleIdList": ["PMC7191112", "32350104"]}, {"Citation": "Olds JL, Kabbani N. Is nicotine exposure linked to cardiopulmonary vulnerability to COVID-19 in the general population? FEBS J 2020;287: 3651\u20135", "ArticleIdList": ["PMC7228237", "32189428"]}, {"Citation": "Kashyap VK, Dhasmana A, Massey A, Kotnala S, Zafar N, Jaggi M, Yallapu MM, Chauhan SC. Smoking and COVID-19: adding fuel to the flame. Int J Mol Sci 2020;21:6581", "ArticleIdList": ["PMC7555793", "32916821"]}, {"Citation": "Krause RM, Buisson B, Bertrand S, Corringer P-J, Galzi J-L, Changeux J-P, Bertrand D. Ivermectin: a positive allosteric effector of the \u03b17 neuronal nicotinic acetylcholine receptor. Mol Pharmacol 1998;53:283\u201394", "ArticleIdList": ["9463487"]}, {"Citation": "Chaccour C, Abizanda G, Irigoyen-Barrio \u00c1, Casellas A, Aldaz A, Mart\u00ednez-Gal\u00e1n F, Hammann F, Gil AG. Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats. Sci Rep 2020;10:17073.", "ArticleIdList": ["PMC7555481", "33051517"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "6", "Day": "11", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "9", "Day": "3", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "6", "Day": "10", "Hour": "6", "Minute": "32"}, {"Year": "2023", "Month": "2", "Day": "1"}], "PublicationStatus": "ppublish", "ArticleIdList": ["35686662", "PMC9442455", "10.1177/15353702221099579"]}}], "PubmedBookArticle": []}